Targeted Oncology· @TargetedOnc · X·· 23 小时前评分70
正文 · 原文
Starting with breast cancer at #ESMO26. KEYNOTE-B49 asks whether pembrolizumab + chemotherapy can improve outcomes in HR+/HER2− advanced disease. I’m particularly interested in PD-L1 selection, OS, toxicity & where this fits after CDK4/6 inhibitors. Highlights from the abstract
89 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Targeted Oncology · x.com